- Home
- DDS vs JAZZ Comparison
DDS vs JAZZ Comparison
Compare DDS & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DDS
- JAZZ
- Stock Information
- Founded
- DDS 1938
- JAZZ 2003
- Country
- DDS United States
- JAZZ Ireland
- Employees
- DDS N/A
- JAZZ N/A
- Industry
- DDS Department/Specialty Retail Stores
- JAZZ Biotechnology: Pharmaceutical Preparations
- Sector
- DDS Consumer Discretionary
- JAZZ Health Care
- Exchange
- DDS Nasdaq
- JAZZ Nasdaq
- Market Cap
- DDS 7.3B
- JAZZ 7.7B
- IPO Year
- DDS N/A
- JAZZ 2007
- Fundamental
- Price
- DDS $577.28
- JAZZ $129.50
- Analyst Decision
- DDS Sell
- JAZZ Strong Buy
- Analyst Count
- DDS 3
- JAZZ 14
- Target Price
- DDS $394.33
- JAZZ $178.93
- AVG Volume (30 Days)
- DDS 149.0K
- JAZZ 745.7K
- Earning Date
- DDS 08-14-2025
- JAZZ 11-05-2025
- Dividend Yield
- DDS 4.53%
- JAZZ N/A
- EPS Growth
- DDS N/A
- JAZZ N/A
- EPS
- DDS 36.27
- JAZZ N/A
- Revenue
- DDS $6,585,731,000.00
- JAZZ $4,086,695,000.00
- Revenue This Year
- DDS N/A
- JAZZ $5.65
- Revenue Next Year
- DDS N/A
- JAZZ $5.79
- P/E Ratio
- DDS $15.82
- JAZZ N/A
- Revenue Growth
- DDS N/A
- JAZZ 4.52
- 52 Week Low
- DDS $282.24
- JAZZ $95.49
- 52 Week High
- DDS $579.55
- JAZZ $148.06
- Technical
- Relative Strength Index (RSI)
- DDS 71.97
- JAZZ 67.67
- Support Level
- DDS $519.06
- JAZZ $127.52
- Resistance Level
- DDS $553.18
- JAZZ $133.00
- Average True Range (ATR)
- DDS 18.27
- JAZZ 2.90
- MACD
- DDS 3.82
- JAZZ 0.72
- Stochastic Oscillator
- DDS 97.32
- JAZZ 77.99
About DDS Dillard's Inc.
Dillard's Inc is an American fashion apparel, cosmetics, and home furnishings retailer. Its stores offer a large variety of merchandise and feature products from both national and exclusive brand sources. The company also operates a general contracting construction company, CDI Contractors. CDI Contractors' business includes constructing and remodelling stores for Dillards. The merchandise selections include exclusive brand merchandise such as Antonio Melani, Gianni Bini, Daniel Cremieux, Roundtree & Yorke, and private-label merchandise, among others. The company operates in two business segments; Retail Operations and Construction. The Retail Operations segment generates maximum revenue for the company.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.